Today's Date
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
(
PAUSE
)
ITN Protocol #:
ITN059AI
Branded Name:
PAUSE
ClinicalTrials.Gov ID:
NCT01999868Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Complete
Summary:
Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris
Clinical Operations Associate Director
Clinical Operations Manager
ITN Biologist
ITN Biostat
ITN Clinical Trial Physician
NIAID Project Manager
Rho Data Manager
Rho Scientist
Study Personnel:
